| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
Simultaneous metadoxine therapy greatly suppressed adipogenic differentiation in a dose-dependent manner. Metadoxine therapy from day 4 to day 8 is essential to suppress MDI-induced preadipocyte differentiation [1]. Metadoxine reduces glutathione depletion and the increase in ethanol- and acetaldehyde-induced lipid peroxidative damage in HepG2 cells. In hepatic stellate cells, metadoxine inhibits the acetaldehyde-induced increase in collagen and the reduction of TNF-α release. Therefore, metadoxine may be utilized to prevent early damage in alcoholic liver disease, as it avoids redox imbalance in hepatocytes and prevents TNF-α production, one of the earliest events in liver damage [2].
|
|---|---|
| References |
| Molecular Formula |
C8H11NO3.C5H7NO3
|
|---|---|
| Molecular Weight |
298.3
|
| Exact Mass |
298.116
|
| CAS # |
74536-44-0
|
| PubChem CID |
115198
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
491.9ºC at 760 mmHg
|
| Melting Point |
102-104ºC
|
| Flash Point |
251.3ºC
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
297
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=NC=C(C(=C1O)CO)CO.C1CC(=O)N[C@@H]1C(=O)O
|
| InChi Key |
RYKKQQUKJJGFMN-HVDRVSQOSA-N
|
| InChi Code |
InChI=1S/C8H11NO3.C5H7NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5;7-4-2-1-3(6-4)5(8)9/h2,10-12H,3-4H2,1H3;3H,1-2H2,(H,6,7)(H,8,9)/t;3-/m.0/s1
|
| Chemical Name |
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2S)-5-oxopyrrolidine-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 155 mg/mL (~519.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (335.24 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3523 mL | 16.7616 mL | 33.5233 mL | |
| 5 mM | 0.6705 mL | 3.3523 mL | 6.7047 mL | |
| 10 mM | 0.3352 mL | 1.6762 mL | 3.3523 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
